{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T07:40:54Z","timestamp":1775634054769,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Advanced systemic sclerosis-associated interstitial lung disease (SSc-ILD) can be treated with lung transplantation. There is limited data on lung transplantation outcomes in patients with SSc-ILD, in non-Western populations.We assessed survival data of patients with SSc-ILD, on the lung transplant (LT) waiting list, and evaluated post-transplant outcomes in patients from an Asian LT center. In this single-center retrospective study, 29 patients with SSc-ILD, registered for deceased LT at Kyoto University Hospital, between 2010 and 2022, were identified. We investigated post-transplant outcomes in recipients who underwent LT for SSc-ILD, between February 2002 and April 2022. Ten patients received deceased-donor LT (34%), two received living-donor LT (7%), seven died waiting for LT (24%), and ten survived on the waiting list (34%). Median duration from registration to deceased-donor LT was 28.9\u00a0months and that from registration to living-donor LT or death was 6.5\u00a0months. Analysis of 15 recipients showed improved forced vital capacity with a median of 55.1% at baseline, 65.8% at 6\u00a0months, and 80.3% at 12\u00a0months post-transplant. The 5-year survival rate for post-transplant patients with SSc-ILD was 86.2%. The higher post-transplant survival rate at our institute than previously reported suggests that lung transplantation is acceptable in Asian patients with SSc-ILD.<\/jats:p>","DOI":"10.1038\/s41598-023-37141-w","type":"journal-article","created":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T12:16:32Z","timestamp":1687436192000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prognosis of patients with systemic sclerosis-related interstitial lung disease on the lung transplant waiting list: a retrospective study"],"prefix":"10.1038","volume":"13","author":[{"given":"Yoichi","family":"Nakayama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6247-0647","authenticated-orcid":false,"given":"Ran","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Handa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Ohsumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshito","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yojiro","family":"Yutaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satona","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Ikezoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiminobu","family":"Tanizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirei","family":"Shirakashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Hiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Kitagori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Akizuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Yoshifuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Date","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Morinobu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,22]]},"reference":[{"key":"37141_CR1","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1136\/ard.2009.114264","volume":"69","author":"AJ Tyndall","year":"2010","unstructured":"Tyndall, A. J. et al. Causes and risk factors for death in systemic sclerosis: A study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann. Rheum. Dis. 69, 1809\u20131815. https:\/\/doi.org\/10.1136\/ard.2009.114264 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"37141_CR2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.semarthrit.2017.03.019","volume":"47","author":"V Hax","year":"2017","unstructured":"Hax, V. et al. Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis. Semin. Arthritis Rheum. 47, 228\u2013234. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.03.019 (2017).","journal-title":"Semin. Arthritis Rheum."},{"key":"37141_CR3","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1002\/art.22204","volume":"54","author":"RK Hoyles","year":"2006","unstructured":"Hoyles, R. K. et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 54, 3962\u20133970. https:\/\/doi.org\/10.1002\/art.22204 (2006).","journal-title":"Arthritis Rheum."},{"key":"37141_CR4","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/rheumatology\/kei211","volume":"45","author":"SNC Liossis","year":"2006","unstructured":"Liossis, S. N. C., Bounas, A. & Andonopoulos, A. P. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology 45, 1005\u20131008. https:\/\/doi.org\/10.1093\/rheumatology\/kei211 (2006).","journal-title":"Rheumatology"},{"key":"37141_CR5","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler, O. et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N. Engl. J. Med. 380, 2518\u20132528. https:\/\/doi.org\/10.1056\/NEJMoa1903076 (2019).","journal-title":"N. Engl. J. Med."},{"key":"37141_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/s0022-5223(03)00600-7","volume":"126","author":"G Thabut","year":"2003","unstructured":"Thabut, G. et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J. Thorac. Cardiovasc. Surg. 126, 469\u2013475. https:\/\/doi.org\/10.1016\/s0022-5223(03)00600-7 (2003).","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"37141_CR7","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.healun.2021.01.1391","volume":"40","author":"JG Natalini","year":"2021","unstructured":"Natalini, J. G. et al. Risk of primary graft dysfunction following lung transplantation in selected adults with connective tissue disease-associated interstitial lung disease. J. Heart Lung Transplant. 40, 351\u2013358. https:\/\/doi.org\/10.1016\/j.healun.2021.01.1391 (2021).","journal-title":"J. Heart Lung Transplant."},{"key":"37141_CR8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccm.2010.05.003","volume":"31","author":"JC Lee","year":"2010","unstructured":"Lee, J. C. & Ahya, V. N. Lung transplantation in autoimmune diseases. Clin. Chest Med. 31, 589\u2013603. https:\/\/doi.org\/10.1016\/j.ccm.2010.05.003 (2010).","journal-title":"Clin. Chest Med."},{"key":"37141_CR9","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.athoracsur.2017.09.038","volume":"105","author":"EY Chan","year":"2018","unstructured":"Chan, E. Y. et al. Long-term survival in bilateral lung transplantation for scleroderma-related lung disease. Ann. Thorac. Surg. 105, 893\u2013900. https:\/\/doi.org\/10.1016\/j.athoracsur.2017.09.038 (2018).","journal-title":"Ann. Thorac. Surg."},{"key":"37141_CR10","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1513\/AnnalsATS.201512-806OC","volume":"13","author":"CH Miele","year":"2016","unstructured":"Miele, C. H. et al. Lung transplant outcomes in systemic sclerosis with significant esophageal dysfunction. A comprehensive single-center experience. Ann. Am. Thorac. Soc. 13, 793\u2013802. https:\/\/doi.org\/10.1513\/AnnalsATS.201512-806OC (2016).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"37141_CR11","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1513\/AnnalsATS.201503-177OC","volume":"13","author":"MM Crespo","year":"2016","unstructured":"Crespo, M. M. et al. Lung transplant in patients with scleroderma compared with pulmonary fibrosis. Short- and long-term outcomes. Ann. Am. Thorac. Soc. 13, 784\u201392. https:\/\/doi.org\/10.1513\/AnnalsATS.201503-177OC (2016).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"37141_CR12","doi-asserted-by":"publisher","first-page":"e12797","DOI":"10.7759\/cureus.12797","volume":"13","author":"A Minalyan","year":"2021","unstructured":"Minalyan, A., Gabrielyan, L., Khanal, S., Basyal, B. & Derk, C. Systemic sclerosis: Current state and survival after lung transplantation. Cureus 13, e12797. https:\/\/doi.org\/10.7759\/cureus.12797 (2021).","journal-title":"Cureus"},{"key":"37141_CR13","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.healun.2021.07.014","volume":"40","author":"MM Crespo","year":"2021","unstructured":"Crespo, M. M. et al. ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part I: Epidemiology, assessment of extrapulmonary conditions, candidate evaluation, selection criteria, and pathology statements. J. Heart Lung Transplant. 40, 1251\u20131266. https:\/\/doi.org\/10.1016\/j.healun.2021.07.014 (2021).","journal-title":"J. Heart Lung Transplant."},{"key":"37141_CR14","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/art.1780230510","volume":"23","author":"AT Masi","year":"1980","unstructured":"Masi, A. T. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 23, 581\u201390. https:\/\/doi.org\/10.1002\/art.1780230510 (1980).","journal-title":"Arthritis Rheum."},{"key":"37141_CR15","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen, F. et al. 2013 classification criteria for systemic sclerosis: An American College of Rheumatology\/European League against rheumatism collaborative initiative. Arthritis Rheum. 65, 2737\u20132747. https:\/\/doi.org\/10.1002\/art.38098 (2013).","journal-title":"Arthritis Rheum."},{"key":"37141_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.healun.2014.06.014","volume":"34","author":"D Weill","year":"2015","unstructured":"Weill, D. et al. A consensus document for the selection of lung transplant candidates: 2014\u2013an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J. Heart Lung Transplant. 34, 1\u201315. https:\/\/doi.org\/10.1016\/j.healun.2014.06.014 (2015).","journal-title":"J. Heart Lung Transplant."},{"key":"37141_CR17","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.healun.2006.03.011","volume":"25","author":"JB Orens","year":"2006","unstructured":"Orens, J. B. et al. International guidelines for the selection of lung transplant candidates: 2006 update\u2013a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J. Heart Lung Transplant. 25, 745\u2013755. https:\/\/doi.org\/10.1016\/j.healun.2006.03.011 (2006).","journal-title":"J. Heart Lung Transplant."},{"key":"37141_CR18","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1097\/00007890-199810150-00033","volume":"17","author":"JR Maurer","year":"1998","unstructured":"Maurer, J. R., Frost, A. E., Estenne, M., Higenbottam, T. & Glanville, A. R. International guidelines for the selection of lung transplant candidates. The International Society for Heart and Lung Transplantation, the American Thoracic Society, the American Society of Transplant Physicians, the European Respiratory Society. J. Heart Lung Transplant. 17, 703\u20139. https:\/\/doi.org\/10.1097\/00007890-199810150-00033 (1998).","journal-title":"J. Heart Lung Transplant."},{"key":"37141_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11748-022-01861-z","volume":"71","author":"S Nagata","year":"2023","unstructured":"Nagata, S. et al. Assessment of listing criteria for lung transplant candidates with interstitial lung disease. Gen. Thorac. Cardiovasc. Surg. 71, 20\u201326. https:\/\/doi.org\/10.1007\/s11748-022-01861-z (2023).","journal-title":"Gen. Thorac. Cardiovasc. Surg."},{"key":"37141_CR20","doi-asserted-by":"publisher","first-page":"6594","DOI":"10.21037\/jtd-2021-07","volume":"13","author":"D Nakajima","year":"2021","unstructured":"Nakajima, D. & Date, H. Living-donor lobar lung transplantation. J. Thorac. Dis. 13, 6594\u20136601. https:\/\/doi.org\/10.21037\/jtd-2021-07 (2021).","journal-title":"J. Thorac. Dis."},{"key":"37141_CR21","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","volume":"177","author":"NSL Goh","year":"2008","unstructured":"Goh, N. S. L. et al. Interstitial lung disease in systemic sclerosis: A simple staging system. Am. J. Respir. Crit. Care Med. 177, 1248\u20131254. https:\/\/doi.org\/10.1164\/rccm.200706-877OC (2008).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"37141_CR22","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda, Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 48, 452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244 (2013).","journal-title":"Bone Marrow Transplant."},{"key":"37141_CR23","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00408-015-9767-x","volume":"193","author":"D Bennett","year":"2015","unstructured":"Bennett, D. et al. Mortality on the waiting list for lung transplantation in patients with idiopathic pulmonary fibrosis: A single-centre experience. Lung 193, 677\u2013681. https:\/\/doi.org\/10.1007\/s00408-015-9767-x (2015).","journal-title":"Lung"},{"key":"37141_CR24","first-page":"235","volume":"33","author":"NC De Oliveira","year":"2016","unstructured":"De Oliveira, N. C. et al. Lung transplantation for high-risk patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc. Diffuse Lung Dis. 33, 235\u2013241 (2016).","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"37141_CR25","doi-asserted-by":"publisher","first-page":"e0183171","DOI":"10.1371\/journal.pone.0183171","volume":"12","author":"K Ikezoe","year":"2017","unstructured":"Ikezoe, K. et al. Prognostic factors and outcomes in Japanese lung transplant candidates with interstitial lung disease. PLoS One 12, e0183171. https:\/\/doi.org\/10.1371\/journal.pone.0183171 (2017).","journal-title":"PLoS One"},{"key":"37141_CR26","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.resinv.2021.03.006","volume":"59","author":"S Miyahara","year":"2021","unstructured":"Miyahara, S. et al. Elucidation of prognostic factors and the effect of anti-fibrotic therapy on waitlist mortality in lung transplant candidates with idiopathic interstitial pneumonias. Respir. Investig. 59, 428\u2013435. https:\/\/doi.org\/10.1016\/j.resinv.2021.03.006 (2021).","journal-title":"Respir. Investig."},{"key":"37141_CR27","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s12890-021-01760-8","volume":"21","author":"T Hirama","year":"2021","unstructured":"Hirama, T. et al. Waiting time and mortality rate on lung transplant candidates in Japan: A single-center retrospective cohort study. BMC Pulm. Med. 21, 390. https:\/\/doi.org\/10.1186\/s12890-021-01760-8 (2021).","journal-title":"BMC Pulm. Med."},{"key":"37141_CR28","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1002\/art.38029","volume":"65","author":"G Lef\u00e8vre","year":"2013","unstructured":"Lef\u00e8vre, G. et al. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: A systematic review and meta-analysis. Arthritis Rheum. 65, 2412\u20132423. https:\/\/doi.org\/10.1002\/art.38029 (2013).","journal-title":"Arthritis Rheum."},{"key":"37141_CR29","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1002\/art.40862","volume":"71","author":"A Young","year":"2019","unstructured":"Young, A. et al. Prevalence, treatment, and outcomes of coexistent pulmonary hypertension and interstitial lung disease in systemic sclerosis. Arthritis Rheumatol. 71, 1339\u20131349. https:\/\/doi.org\/10.1002\/art.40862 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"37141_CR30","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1038\/ctg.2017.30","volume":"8","author":"A Tangaroonsanti","year":"2017","unstructured":"Tangaroonsanti, A. et al. Impaired esophageal motility and clearance post-lung transplant: Risk for chronic allograft failure. Clin. Transl. Gastroenterol. 8, e102. https:\/\/doi.org\/10.1038\/ctg.2017.30 (2017).","journal-title":"Clin. Transl. Gastroenterol."},{"key":"37141_CR31","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1183\/09031936.00139809","volume":"36","author":"R Saggar","year":"2010","unstructured":"Saggar, R. et al. Systemic sclerosis and bilateral lung transplantation: A single centre experience. Eur. Respir. J. 36, 893\u2013900. https:\/\/doi.org\/10.1183\/09031936.00139809 (2010).","journal-title":"Eur. Respir. J."},{"key":"37141_CR32","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1097\/TP.0b013e3182845f23","volume":"95","author":"PD Sottile","year":"2013","unstructured":"Sottile, P. D. et al. Outcomes in systemic sclerosis-related lung disease after lung transplantation. Transplantation 95, 975\u2013980. https:\/\/doi.org\/10.1097\/TP.0b013e3182845f23 (2013).","journal-title":"Transplantation"},{"key":"37141_CR33","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/art.39021","volume":"67","author":"EJ Bernstein","year":"2015","unstructured":"Bernstein, E. J. et al. Survival of adults with systemic sclerosis following lung transplantation: A nationwide cohort study. Arthritis Rheumatol. 67, 1314\u20131322. https:\/\/doi.org\/10.1002\/art.39021 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"37141_CR34","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.healun.2021.07.016","volume":"40","author":"CA Bermudez","year":"2021","unstructured":"Bermudez, C. A. et al. ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part II: Cardiac, surgical, perioperative, operative, and post-operative challenges and management statements. J. Heart Lung Transplant. 40, 1267\u20131278. https:\/\/doi.org\/10.1016\/j.healun.2021.07.016 (2021).","journal-title":"J. Heart Lung Transplant."},{"key":"37141_CR35","doi-asserted-by":"publisher","first-page":"e0249758","DOI":"10.1371\/journal.pone.0249758","volume":"16","author":"FJ Gonzalez","year":"2021","unstructured":"Gonzalez, F. J. et al. The influence of the native lung on early outcomes and survival after single lung transplantation. PLoS One 16, e0249758. https:\/\/doi.org\/10.1371\/journal.pone.0249758 (2021).","journal-title":"PLoS One"},{"key":"37141_CR36","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.healun.2009.04.023","volume":"28","author":"CS King","year":"2009","unstructured":"King, C. S. et al. Native lung complications in single-lung transplant recipients and the role of pneumonectomy. J. Heart Lung Transplant. 28, 851\u2013856. https:\/\/doi.org\/10.1016\/j.healun.2009.04.023 (2009).","journal-title":"J. Heart Lung Transplant."},{"key":"37141_CR37","first-page":"271","volume":"55","author":"The Japanese Society of Lung and Heart-Lung Transplantation","year":"2020","unstructured":"The Japanese Society of Lung and Heart-Lung Transplantation. Registry report of Japanese lung transplantation 2020. Transplantation 55, 271\u2013276 (2020).","journal-title":"Transplantation"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-37141-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-37141-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-37141-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T12:23:25Z","timestamp":1687436605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-37141-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["37141"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-37141-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,22]]},"assertion":[{"value":"24 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RN has collaborated with Medical & Biological Laboratories Co., Ltd. and has received speaking fees from Astellas Pharma, Boehringer Ingelheim, Asahi Kasei, Japan Blood Products Organization, and Nihon Pharmaceutical outside the submitted work. HY has received a lecture fee from Chugai, Janssen, and Boehringer Ingelheim outside of this work. YN, TH, AO, YYamada, DN, YYutaka, ST, SH, KI, KT, MS, RH, HT, KK, SA, HD, and AM declare no potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10150"}}